Real-World Results of Low-Dose Tirzepatide for Weight Loss in Italy

Even at the lowest doses (2.5-5 mg), tirzepatide produces meaningful weight loss and metabolic improvements in real-world Italian obesity patients.

Barrea, Luigi et al.·EXCLI journal·2026·
RPEP-148462026RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Not classified
Evidence
Not graded
Sample
Not reported

What This Study Found

Tirzepatide at 2.5 mg and 5.0 mg produced significant short-term weight loss and metabolic improvements in a real-world outpatient obesity population, confirming clinical trial benefits translate to routine practice.

Key Numbers

How They Did This

Retrospective multicenter study across Italian Society of Obesity (SIO) Campania Region clinics evaluating short-term outcomes of tirzepatide 2.5 mg and 5.0 mg in adults with obesity.

Why This Research Matters

Many patients remain on lower tirzepatide doses for extended periods. Confirming these doses work in real-world settings — not just controlled trials — is essential for clinical confidence.

The Bigger Picture

Real-world evidence increasingly complements clinical trial data, helping clinicians set realistic expectations and supporting broader access to newer obesity medications.

What This Study Doesn't Tell Us

Retrospective design with short follow-up. Single-region study in Italy may not generalize to other populations. No control group for comparison.

Questions This Raises

  • ?How does real-world weight loss at maximum tirzepatide doses compare to trial results?
  • ?Do patients who start at lower doses achieve similar long-term outcomes as those who titrate up quickly?

Trust & Context

Key Stat:
Real-world confirmation Low-dose tirzepatide benefits validated outside clinical trial settings
Evidence Grade:
Retrospective real-world study without a control group — provides practical data but lower evidence grade than RCTs.
Study Age:
Published in 2026; among the first real-world tirzepatide studies from Europe.
Original Title:
Real-world data of tirzepatide in obesity management: a multicenter study by the Italian Society of Obesity - Campania Region.
Published In:
EXCLI journal, 25, 191-203 (2026)
Database ID:
RPEP-14846

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

Does tirzepatide work at low doses?

Yes, this real-world study confirms that even the starting doses of 2.5 mg and 5 mg tirzepatide produce meaningful weight loss and metabolic improvements in routine clinical practice.

How does real-world tirzepatide compare to clinical trials?

Early real-world data suggests benefits are consistent with trial results, though individual responses vary. The key finding is that lower doses still provide clinically relevant improvements.

Read More on RethinkPeptides

Related articles coming soon.

Cite This Study

RPEP-14846·https://rethinkpeptides.com/research/RPEP-14846

APA

Barrea, Luigi; Verde, Ludovica; Galasso, Martina; Patrone, Renato; Digitale, Lucia; Limardi, Alessandro; Orio, Marcello; Ragozzino, Giovanni; Digitale, Luigi; Salvatore, Vittorio; Savoia, Antonella; Savastano, Silvia; Colao, Annamaria; Muscogiuri, Giovanna. (2026). Real-world data of tirzepatide in obesity management: a multicenter study by the Italian Society of Obesity - Campania Region.. EXCLI journal, 25, 191-203. https://doi.org/10.17179/excli2025-9067

MLA

Barrea, Luigi, et al. "Real-world data of tirzepatide in obesity management: a multicenter study by the Italian Society of Obesity - Campania Region.." EXCLI journal, 2026. https://doi.org/10.17179/excli2025-9067

RethinkPeptides

RethinkPeptides Research Database. "Real-world data of tirzepatide in obesity management: a mult..." RPEP-14846. Retrieved from https://rethinkpeptides.com/research/barrea-2026-realworld-data-of-tirzepatide

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.